We are live on
!
Find out more
LCM
Laurion Capital Management Portfolio holdings
AUM
$2.29B
1-Year Est. Return
75.73%
This Fund
S&P 500
This Quarter
Est. Return
+6.97%
1 Year Est. Return
+75.73%
3 Year Est. Return
+162.63%
5 Year Est. Return
+130.38%
10 Year Est. Return
+388.8%
AUM
$17.9B
AUM Growth
+$3.18B
(+22%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.82%
Top 10 Holdings %
Top 10 Hldgs %
38.29%
Holding
721
New
293
Increased
98
Reduced
124
Closed
140
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
T-Mobile US
TMUS
|
+$124M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$95.2M |
| 3 |
Pliant Therapeutics
PLRX
|
+$74.8M |
| 4 |
Microsoft
MSFT
|
+$72.6M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$56.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$123M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$60.4M |
| 3 |
Emerson Electric
EMR
|
+$55M |
| 4 |
Home Depot
HD
|
+$54.8M |
| 5 |
Comcast
CMCSA
|
+$53.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 5.44% |
| 2 | Technology | 2.51% |
| 3 | Communication Services | 1.69% |
| 4 | Utilities | 1.38% |
| 5 | Industrials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Kinsale Capital Group
KNSL
$8.39B
| $1.17M | 0.01% |
+3,132
| New | +$1.04M |
|
352
ExxonMobil
XOM
$654B
| $1.15M | 0.01% |
+10,756
| New | +$1.17M |
|
353
Warner Bros
WBD
$67.3B
| $1.12M | 0.01% |
+89,112
| New | +$1.16M |
|
354
PUT
Phillips 66
PSX
$84.2B
| $1.12M | 0.01% |
+11,700
| New | +$1.14M |
|
355
Ferguson
FERG
$51.5B
| $1.11M | 0.01% |
7,071
-42,724
| -86% | -$6.08M |
|
356
Texas Roadhouse
TXRH
$13.8B
| $1.11M | 0.01% |
+9,895
| New | +$1.09M |
|
357
Morgan Stanley
MS
$340B
| $1.11M | 0.01% |
12,985
-441,526
| -97% | -$37.8M |
|
358
Atour Lifestyle Holdings
ATAT
$4.84B
| $1.1M | 0.01% |
+68,000
| New | +$1.32M |
|
359
Brady Corp
BRC
$4.57B
| $1.08M | 0.01% |
+22,666
| New | +$1.14M |
|
360
ASML
ASML
$678B
| $1.07M | 0.01% |
+1,481
| New | +$1.01M |
|
361
Cardiff Oncology
CRDF
$75.2M
| $1.06M | 0.01% |
722,100
| – | – |
|
362
Public Storage
PSA
$60B
| $1.02M | 0.01% |
3,500
| – | – |
|
363
Agree Realty
ADC
$9.25B
| $1.02M | 0.01% |
+15,584
| New | +$1.03M |
|
364
State Street Financial Select Sector SPDR ETF
XLF
$59B
| $1.01M | 0.01% |
+30,000
| New | +$979K |
|
365
Crocs
CROX
$6.58B
| $1.01M | 0.01% |
+8,961
| New | +$1.07M |
|
|
VIRX
366
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $984K | 0.01% |
698,000
| – | – |
|
367
RLI Corp
RLI
$5.86B
| $966K | 0.01% |
+14,152
| New | +$940K |
|
|
KRTX
368
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $964K | 0.01% |
+4,444
| New | +$952K |
|
369
CALL
ServiceNow
NOW
$128B
| $955K | 0.01% |
8,500
-1,491,000
| -99% | -$149M |
|
370
Medpace
MEDP
$16.5B
| $940K | 0.01% |
+3,914
| New | +$813K |
|
|
VIGL
371
DELISTED
Vigil Neuroscience
VIGL
| $937K | 0.01% |
99,689
-30,511
| -23% | -$288K |
|
|
CYT
372
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $935K | 0.01% |
359,500
| – | – |
|
373
Murphy USA
MUSA
$9.97B
| $918K | 0.01% |
+2,951
| New | +$826K |
|
374
DexCom
DXCM
$32.6B
| $914K | 0.01% |
+7,115
| New | +$861K |
|
375
Frontline
FRO
$8.83B
| $914K | 0.01% |
+62,871
| New | +$940K |
|
Similar funds
AFM
GCP
LCM
MAP
MA
NSAM
ABI
OCM
Laurion Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Laurion Capital Management held 721 positions worth $17.9B, up 22% from $14.7B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Laurion Capital Management deployed $2.11B of net new capital in Q2 2023, opening 293 new positions and adding to 98 existing holdings. Its largest new stake was Pliant Therapeutics: 3,158,570 shares worth $57.2M.
By sector, the portfolio is most concentrated in Healthcare at 5.4% of assets, down from 6.6% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Viatris, an estimated $123M trimmed.
- Laurion Capital Management's largest Q2 2023 buy was Pliant Therapeutics: 3,158,570 shares worth $57.2M.
- Laurion Capital Management added most to T-Mobile US in Q2 2023, an estimated $124M increase.
- Laurion Capital Management's biggest Q2 2023 reduction was Viatris, cutting an estimated $123M.
- Laurion Capital Management fully exited CATALENT, INC. in Q2 2023, selling an estimated $60.4M.
- Laurion Capital Management's ten largest holdings make up 38% of its $17.9B portfolio in Q2 2023.
- Laurion Capital Management opened 293 new positions and closed 140 in Q2 2023.
- Laurion Capital Management's portfolio value rose 22% quarter-over-quarter to $17.9B.
Based on Laurion Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.